Safety, pharmacokinetics, and biomarkers of F-652, a recombinant human interleukin-22 dimer, in healthy subjects.
Adult
Bacterial Infections
/ drug therapy
Biomarkers
/ blood
Cytokines
/ blood
Dimerization
Dose-Response Relationship, Drug
Double-Blind Method
Drug-Related Side Effects and Adverse Reactions
Healthy Volunteers
Humans
Immunoglobulin Constant Regions
/ genetics
Inflammation Mediators
/ blood
Infusions, Intravenous
Injection Site Reaction
/ etiology
Interleukins
/ genetics
Male
Recombinant Fusion Proteins
/ adverse effects
Serum Amyloid A Protein
/ metabolism
Wound Healing
/ drug effects
Young Adult
Interleukin-22
F-652
Interleukin-22
Pharmacodynamics
Pharmacokinetics
Safety
Journal
Cellular & molecular immunology
ISSN: 2042-0226
Titre abrégé: Cell Mol Immunol
Pays: China
ID NLM: 101242872
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
19
12
2017
accepted:
26
03
2018
pubmed:
20
4
2018
medline:
1
8
2020
entrez:
20
4
2018
Statut:
ppublish
Résumé
F-652 is a recombinant fusion protein consisting of two human interleukin-22 (IL-22) molecules linked to an immunoglobulin constant region (IgG
Identifiants
pubmed: 29670279
doi: 10.1038/s41423-018-0029-8
pii: 10.1038/s41423-018-0029-8
pmc: PMC6474205
doi:
Substances chimiques
Biomarkers
0
Cytokines
0
Immunoglobulin Constant Regions
0
Inflammation Mediators
0
Interleukins
0
Recombinant Fusion Proteins
0
Serum Amyloid A Protein
0
Types de publication
Clinical Trial, Phase I
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
473-482Commentaires et corrections
Type : CommentIn
Références
Sabat, R., Ouyang, W. & Wolk, K. Therapeutic opportunities of the IL-22-IL-22R1 system. Nat. Rev. Drug. Discov. 13, 21–38 (2014).
doi: 10.1038/nrd4176
Dumoutier, L., Van Roost, E., Colau, D. & Renauld, J. C. Human interleukin-10-related T cell-derived inducible factor: molecular cloning and functional characterization as an hepatocyte-stimulating factor. Proc. Natl Acad. Sci. USA 97, 10144–10149 (2000).
doi: 10.1073/pnas.170291697
Xie, M. H. et al. Interleukin (IL)-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R. J. Biol. Chem. 275, 31335–31339 (2000).
doi: 10.1074/jbc.M005304200
Alam, M. S. et al. Notch signaling drives IL-22 secretion in CD4+T cells by stimulating the aryl hydrocarbon receptor. Proc. Natl Acad. Sci. USA 107, 5943–5948 (2010).
doi: 10.1073/pnas.0911755107
Pestka, S. et al. Interleukin-10 and related cytokines and receptors. Annu. Rev. Immunol. 22, 929–979 (2004).
doi: 10.1146/annurev.immunol.22.012703.104622
Bleicher, L. et al. Crystal structure of the IL-22/IL-22R1 complex and its implications for the IL-22 signaling mechanism. FEBS Lett. 582, 2985–2992 (2008).
doi: 10.1016/j.febslet.2008.07.046
Commins, S., Steinke, J. W. & Borish, L. The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29. J. Allergy Clin. Immunol. 121, 1108–1111 (2008).
doi: 10.1016/j.jaci.2008.02.026
Lejeune, D. et al. Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct from IL-10. J. Biol. Chem. 277, 33676–33682 (2002).
doi: 10.1074/jbc.M204204200
Pickert, G. et al. STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. J. Exp. Med. 206, 1465–1472 (2009).
doi: 10.1084/jem.20082683
Wolk, K., Witte, E., Witte, K., Warszawska, K. & Sabat, R. Biology of interleukin-22. Semin. Immunopathol. 32, 17–31 (2010).
doi: 10.1007/s00281-009-0188-x
Gao, B. Hepatoprotective and anti-inflammatory cytokines in alcoholic liver disease. J. Gastroenterol. Hepatol. 27(Suppl. 2), 89–93 (2012).
doi: 10.1111/j.1440-1746.2011.07003.x
Kong, X., Feng, D., Mathews, S. & Gao, B. Hepatoprotective and anti-fibrotic functions of interleukin-22: therapeutic potential for the treatment of alcoholic liver disease. J. Gastroenterol. Hepatol. 28(Suppl. 1), 56–60 (2013).
doi: 10.1111/jgh.12032
Zenewicz, L. A. & Flavell, R. A. Recent advances in IL-22 biology. Int. Immunol. 23, 159–163 (2011).
doi: 10.1093/intimm/dxr001
Pan, H., Hong, F., Radaeva, S. & Gao, B. Hydrodynamic gene delivery of interleukin-22 protects the mouse liver from concanavalin A-, carbon tetrachloride-, and Fas ligand-induced injury via activation of STAT3. Cell. Mol. Immunol. 1, 43–49 (2004).
pubmed: 16212920
Radaeva, S., Sun, R., Pan, H. N., Hong, F. & Gao, B. Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation. Hepatology 39, 1332–1342 (2004).
doi: 10.1002/hep.20184
Ratsimandresy, R. A., Indramohan, M., Dorfleutner, A. & Stehlik, C. The AIM2 inflammasome is a central regulator of intestinal homeostasis through the IL-18/IL-22/STAT3 pathway. Cell. Mol. Immunol. 14, 127–142 (2017).
doi: 10.1038/cmi.2016.35
Nagem, R. A. et al. Crystal structure of recombinant human interleukin-22. Structure 10, 1051–1062 (2002).
doi: 10.1016/S0969-2126(02)00797-9
Nagem, R. A., Ferreira Junior, J. R., Dumoutier, L., Renauld, J. C. & Polikarpov, I. Interleukin-22 and its crystal structure. Vitam. Horm. 74, 77–103 (2006).
doi: 10.1016/S0083-6729(06)74004-3
de Oliveira Neto, M. et al. Interleukin-22 forms dimers that are recognized by two interleukin-22R1 receptor chains. Biophys. J. 94, 1754–1765 (2008).
doi: 10.1529/biophysj.107.112664
Dudakov, J. A., Hanash, A. M. & van den Brink, M. R. Interleukin-22: immunobiology and pathology. Annu. Rev. Immunol. 33, 747–785 (2015).
doi: 10.1146/annurev-immunol-032414-112123
Andoh, A. et al. Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts. Gastroenterology 129, 969–984 (2005).
doi: 10.1053/j.gastro.2005.06.071
Liang, S. C. et al. IL-22 induces an acute-phase response. J. Immunol. 185, 5531–5538 (2010).
doi: 10.4049/jimmunol.0904091
Yang, L. et al. Amelioration of high fat diet induced liver lipogenesis and hepatic steatosis by interleukin-22. J. Hepatol. 53, 339–347 (2010).
doi: 10.1016/j.jhep.2010.03.004
Park, O. et al. In vivo consequences of liver-specific interleukin-22 expression in mice: Implications for human liver disease progression. Hepatology 54, 252–261 (2011).
doi: 10.1002/hep.24339
Ki, S. H. et al. Interleukin-22 treatment ameliorates alcoholic liver injury in a murine model of chronic-binge ethanol feeding: role of signal transducer and activator of transcription 3. Hepatology 52, 1291–1300 (2010).
doi: 10.1002/hep.23837
Hong, F. et al. Interleukin 6 alleviates hepatic steatosis and ischemia/reperfusion injury in mice with fatty liver disease. Hepatology 40, 933–941 (2004).
doi: 10.1002/hep.20400